La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Allakos a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Allakos..

Allakos (NASDAQ:ALLK) Azioni, Catena delle Opzioni

Allakos

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

Allakos Inc

Allkem Ltd

Raymond James analyst Savanthi Syth reiterates Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) with a Market Perform.

News

Reiteration

Analyst Ratings

EVTL

Raymond James Reiterates Market Perform on Vertical Aerospace

B. Riley Securities analyst Hal Goetsch maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Buy and raises the price target from $110 to $150.

Price Target

FOUR

B. Riley Securities Maintains Buy on Shift4 Payments, Raises Price Target to $150

B. Riley Securities analyst Craig Kennison maintains Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Buy and raises the price target from $61 to $85.

SMTC

B. Riley Securities Maintains Buy on Semtech, Raises Price Target to $85

WIIM

Real Good Food Company shares are trading higher. The company requested an extension regarding its Nasdaq delinquency notice.

<h3>The partnership will connect advertisers in a privacy-protective manner to SMB audiences to create more accurate and better-performing B2B marketing campaigns</h3>
REDWOOD CITY, Calif – November 26, 2024&nbsp;– PubMatic, an independent technology company delivering digital advertising's supply chain of the future, announced a new strategic partnership with Intuit's SMB MediaLabs that will make rich first-party SMB audiences available in PubMatic's self-service Convert platform for commerce media. This collaboration will enable publishers and advertisers to access unparalleled data-led targeting capabilities, significantly enhancing B2B marketing campaign performance and accuracy.
Intuit's SMB MediaLabs is a first-of-its-kind media network focused solely on small and medium-sized businesses. It reaches an audience of millions of small and medium businesses leveraging 36 million identifiers through Intuit QuickBooks, while keeping the underlying customer data secure on Intuit's platform. SMB MediaLabs launched in July 2023 as a managed service via insertion orders. Now, in partnership with PubMatic, enterprise-level and large holding company buyers and publishers offering premium, brand-safe inventory across CTV, video, mobile and more will be able to connect marketers to this attractive audience-segment through PubMatic. Plus, SMB MediaLabs advertisers will be able to connect to these data segments directly via PubMatic's self-service Convert platform, a flexible, integrated white-label tech solution for retailers and marketplaces.

INTU

PUBM

Pubmatic Forges Partnership With Intuit SMB Medialabs To Advance B2B Advertising With Privacy-Protective Solutions

B. Riley Securities analyst Eric Wold downgrades Brunswick (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BC#NYSE">BC</a>) from Buy to Neutral and lowers the price target from $95 to $88.

Downgrades

B. Riley Securities Downgrades Brunswick to Neutral, Lowers Price Target to $88

VEEA

Veea shares are trading higher after the company announced partnership  based on MARQUEE's patented SMARTCELL platform. Under the initiative, Veea's decentralized physical infrastructure network will accelerate the introduction of MEC solutions with Edge AI as an extension of the cellular network inftrascuture.

On Monday, the Centers for Medicare &amp; Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.
Included was a final decision related to CMS pricing for Exact Sciences Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) Cologuard Plus, a second-generation test that received FDA <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41185292/fda-clears-exact-sciences-next-generation-colorectal-cancer-diagnostic-test" rel="noreferrer noopener">approval in October</a>.
William Blair writes that the <a target="_blank" href="https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/annual-public-meetings" rel="noreferrer noopener">determinations</a> effectively raise reimbursement by 16% versus the current Medicare rate for the first-generation Cologuard test (to $592 for Cologuard Plus from $509 for Cologuard).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41776963/colorectal-cancer-diagnostic-focused-exact-sciences-stock-plunges-on-weak-annual-gu" rel="noreferrer noopener">Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point</a>
The determination reverses the September preliminary decision but aligns with a proposal made during the public comment period.
The analyst writes that reimbursement for Cologuard Plus will now be calculated based on two components: three times the fee for methylation analysis of Septin-9 ($192 x 3) and the fee for a FIT test ($15.92).
This pricing adjustment is expected to take effect for Medicare volumes when the test officially launches in late first quarter or early second quarter of 2025. Medicare fee-for-service volumes should reflect the new pricing immediately upon launch, with Medicare Advantage following soon after.
The company is also likely to renegotiate commercial contracts for higher pricing, which may gradually roll out over the coming quarters and years.
William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">Outperform rating on the stock.</a>
The analyst highlights that the update is a positive outcome for the company, as it simplifies the process of implementing a price increase compared to the more complex advanced diagnostic laboratory test (ADLT) pathway.
From a financial perspective, this decision is expected to support a moderate pricing boost starting in 2025. Based on William Blair&#8217;s estimates, this could add at least 300 basis points to Cologuard's growth rate next year, which is projected to be around 15% overall.
Exact Sciences said it will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42177702/exact-sciences-advances-breast-cancer-care-with-the-oncotype-dx-test-and-genomic-profiling-researc" rel="noreferrer noopener">scheduled next month</a>.
Price Action: EXAS stock is up 7.60% at $59.33 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42190381/analog-devices-q4-earnings-beats-estimates-automotive-rebound-outlook" target="_blank" rel="noreferrer noopener">Analog Devices Q4 Earnings: Beats Estimates, Automotive Rebound, Cautiously Optimistic Outlook &amp; More</a></li>
</ul>
Illustration of Phrama lab worker created with MidJourney.

Analyst Color

Equities

Health Care

Movers

Trading Ideas

General

EXAS

Why Is Exact Sciences Stock Trading Higher On Monday?

CIMG Shares Resume Trade

Truist Securities analyst Keith Hughes downgrades Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) from Buy to Hold and lowers the price target from $60 to $52.5.

Truist Securities Downgrades Summit Materials to Hold, Lowers Price Target to $52.5

TD Cowen analyst Ryan Langston maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Buy and lowers the price target from $275 to $251.

TD Cowen Maintains Buy on Universal Health Servs, Lowers Price Target to $251

Live On CNBC, Bill Baruch Announces Sold Chubb

Raymond James analyst David Long upgrades Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) from Market Perform to Strong Buy and announces $28 price target.

Upgrades

Raymond James Upgrades Old National to Strong Buy, Announces $28 Price Target

Shares of Maxeon Solar Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) are volatile Tuesday after the company announced a significant restructuring of its business operations. Here&#8217;s <a href="https://www.benzinga.com/quote/MAXN/news">what you need to know.</a>
What To Know: Maxeon Solar announced plans to focus exclusively on the U.S. market, citing its established presence and a planned local manufacturing facility as key elements for growth.
As part of the restructuring, Maxeon has signed a five-year lease for a facility in Albuquerque, New Mexico. The company aims to begin solar panel production at this site in 2026 with an initial planned capacity of 2 gigawatts. This marks the company&#8217;s first step in a broader initiative to establish a domestic solar panel supply chain.
&#8220;As Maxeon intensifies its focus on the U.S. market, our priority is to further expand our growing residential and commercial partner network and support our well-established base of utility-scale customers,&#8221; said George Guo, Maxeon&#8217;s CEO.
See Also: <a href="https://www.benzinga.com/etfs/currency-etfs/24/11/42190765/trumps-tariff-threats-slam-mexican-peso-canadian-dollar-only-the-beginning-of-a-sorely-needed-repricing-expert-warns">Mexican Peso, Canadian Dollar Slide As Ackman Says Trump Will Use Tariffs &#8216;As A Weapon&#8217;</a>
In a move to exit other international markets, Maxeon has reached agreements in principle with TCL Technology Group, its majority shareholder, to sell its sales and marketing operations in Europe, Asia-Pacific and Latin America. TCL plans to integrate the operations into a new unit called TCL SunPower International, which will also acquire Maxeon's manufacturing operations in the Philippines.
Following the transactions, Maxeon will focus solely on the U.S. residential, commercial and utility-scale solar markets. The restructuring aligns with the company&#8217;s strategy to strengthen its U.S. operations and prioritize domestic solar supply chain development.
The agreements between Maxeon and TCL are expected to be finalized by the end of 2024, with the Albuquerque project contingent on securing financing.
&#8220;This strategic re-focusing of our business is designed to keep us closer and more attuned to the needs of our U.S. customer base, allowing us to leverage Maxeon&#8217;s deep experience and top-tier reputation for product innovation and quality that are a result of almost 40 years of technology leadership and investments in intellectual property,&#8221; Guo added.
MAXN Price Action: <a href="http://benzinga.com/quote/maxn">Maxeon Solar shares</a> initially traded up above $10 per share before reversing course and turning negative. The stock was down 3.76% at $7.68 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="553" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26104856/MAXN-1024x553.png" alt="" class="wp-image-665701" style="width:455px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26104856/MAXN-1024x553.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26104856/MAXN-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26104856/MAXN-768x414.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26104856/MAXN.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42193222/orange-taps-openai-meta-to-create-ai-that-speaks-african-languages">Meta, OpenAI, Orange Join Forces To Build AI Models For African Languages</a></li>
</ul>
Photo by Nuno Marques on Unsplash..

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

What's Going On With Maxeon Solar Technologies Stock Today?

Billionaire Elon Musk surprised many people when he bought social media platform Twitter in 2022, and he could be back with another media acquisition in 2025. In a post, he asked about the price of Comcast Corporation&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) cable assets, ahead of <a href="https://www.benzinga.com/news/global/24/11/42081224/comcast-plans-major-cable-networks-spinoff-msnbc-and-cnbc-to-form-new-public-company-report">a planned spinoff.</a>
What Happened: Musk spent $44 billion to acquire Twitter, now known as X, <a href="https://www.benzinga.com/news/23/04/31810229/elon-musk-bought-twitter-1-year-ago-a-look-back-at-whats-happened-since-and-what-could-be-next">back in 2022</a>. The move added to the portfolio of companies owned or controlled by the world's richest man.
Musk could have his eyes set on the cable assets of Comcast Corporation being spun off, which include MSNBC, CNBC, USA, Oxygen, E!, Syfy and Golf Channel. Comcast will keep ownership of the NBC broadcast network, Bravo, NBC Sports, Peacock streaming platform and Universal theme parks.
While Comcast has not placed MSNBC or other assets for sale, choosing instead to spin them off as a separate company, Musk has expressed interest either jokingly or as a foreshadowing of an eventual purchase.
"How much does it cost?" Musk <a href="https://x.com/elonmusk/status/1860037420710080687">tweeted </a>in reply to a post from Donald Trump Jr. saying he had "the funniest idea ever."
Trump Jr. shared a post suggesting that Comcast was looking for a buyer of MSNBC.
While Musk has spoken ill of the "mainstream media" for many years, a purchase of MSNBC or the cable assets from Comcast wouldn't be a huge surprise at this point, given his past purchase of Twitter.
Musk <a href="https://x.com/redletterdave/status/1518585718012059648">posted </a>that he loved Twitter on Dec. 21, 2017, which prompted a user to say "you should buy it then." Musk responded "how much is it" and that post preceded Musk's eventual acquisition of the company.
The billionaire has often said "the most entertaining outcome is the most likely" and an acquisition of MSNBC would certainly be entertaining.
Prediction market Polymarket has a betting market <a href="https://polymarket.com/event/will-elon-musk-buy-msnbc-before-april-2025">open </a>for "Will Elon Musk buy MSNBC?" The market, which has around $520,000 wagered, currently shows a 15% chance that Musk buys MSNBC. The market, which opened for trading on Nov. 22, hit a high of 19% on Nov. 23. The prediction market shows a low probability of Musk announcing an acquisition.
On Polymarket, users deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) network or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). Winning wagers cash out at $1 per contract.
The market will resolve as &#8220;Yes&#8221; if Musk or a Musk-controlled entity announced a plan to acquire MSNBC by March 31, 2025 whether the acquisition has been completed.
<ul>
<li>You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/24/11/42144099/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-44">check out five stocks flying under the radar that deserve your attention.</a></li>
</ul>
Is Musk Serious?: The big question on everyone's mind is whether Musk is serious. Buying MSNBC would add to the billionaire's portfolio of companies and also increase his workload, which comes as he is set to take on a government role co-leading the Department of Government Efficiency.
Musk currently owns or leads X, SpaceX, Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), xAI, The Boring Company, Neuralink and more. While some of these companies count on other individuals as CEO or COO to offset Musk's other time commitments, there likely aren't enough hours in the day for Musk to make an impact at all these companies already on the daily.
"My workload went up from 70 to 80 hours a week to probably 120," Musk said <a href="https://www.benzinga.com/news/22/11/29582707/elon-musks-life-after-twitter-acquisition-i-wake-up-work-go-to-sleep-work-do-that-7-days-a-week-1">after buying Twitter.</a> "Go to sleep, I wake up, work, go to sleep, work, do that 7 days a week."
While Musk is a known workaholic and likely would love the challenge of adding another company to the mix, Tesla shareholders might not love the thought.
As a publicly traded company, Tesla is one of Musk&#8217;s top priorities and frequently faces intense scrutiny for missed milestones and performance targets. If Musk were to devote more time to leading MSNBC after a potential acquisition, it would likely raise concerns among investors and analysts.
Musk is worth $348 billion according to <a href="https://www.bloomberg.com/billionaires/?sref=TBDibEcD">Bloomberg</a>, making him the richest person in the world. Another key question would be how much cash Musk readily has available or if he would need to borrow against his key holdings or sell Tesla stock to complete the acquisition.
The billionaire<a href="https://www.benzinga.com/m-a/22/10/29444090/musk-hasnt-sold-more-tesla-shares-to-fund-44b-twitter-deal-could-overhang-be-gone"> sold Tesla shares </a>in 2022 to help fund the Twitter acquisition, a move some analysts referred to as an overhang on Tesla stock. Tesla stock was down 65% in 2022, marking the worst year since the company went public and one of only two years the stock has been down since going public in 2010.
Why It's Important: A report from <a href="https://www.cnn.com/2024/11/25/media/elon-musk-msnbc-spinoff-cable/index.html">CNN </a>says that at least one billionaire has reached out to express interest in buying MSNBC and it wasn't Musk.
Comcast has not indicated that MSNBC or its other assets are for sale. With plans already in motion for a tax-free spinoff of a new company to shareholders, it would likely require an exceptionally compelling offer to persuade the board or shareholders to consider an alternative course.
While one unnamed billionaire is interested, another told CNN he has no interest.
"I don't think there is anything anyone can do to change the impact of linear TV news. So the answer is no," Mark Cuban told CNN.
CMCSA Price Action: Comcast stock is down 1.5% to $42.54 on Tuesday, versus a 52-week trading range of $36.43 to $47.11. The stocks' year-to-date and five-year returns of negative 1.1% and negative 2.2%, respectively, have greatly trailed the overall market, with the SPDR S&amp;P 500 ETF Trust up 26.4% year-to-date and up 90.1% over the last five years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41142828/elon-musk-bought-x-for-44b-now-fidelity-values-social-media-network-below-10b">Elon Musk Bought X For $44B, Now Fidelity Values Social Media Network Below $10B</a></li>
</ul>
Photo: Shutterstock

Entertainment

Media

$ETH

$MATIC

$USDC

CMCSA

TSLA

Will Elon Musk Buy MSNBC? Recent News Parallels Twitter Acquisition, But Polymarket Shows Low Odds Of A Deal

BTIG analyst Mark Massaro maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and raises the price target from $65 to $75.

BTIG Maintains Buy on Exact Sciences, Raises Price Target to $75

Investors with a lot of money to spend have taken a bearish stance on Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ADBE, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for Adobe.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 60%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $336,059, and 12 are calls, for a total amount of $868,336.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $400.0 to $600.0 for Adobe over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Adobe's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Adobe's substantial trades, within a strike price spectrum from $400.0 to $600.0 over the preceding 30 days.
<h3>Adobe 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732641402_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$13.7</td>
<td>$13.3</td>
<td>$13.3</td>
<td>$550.00</td>
<td>$396.3K</td>
<td align="right">650</td>
<td align="right">25</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$39.6</td>
<td>$39.5</td>
<td>$39.6</td>
<td>$540.00</td>
<td>$79.2K</td>
<td align="right">503</td>
<td align="right">27</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$153.4</td>
<td>$151.5</td>
<td>$152.33</td>
<td>$400.00</td>
<td>$76.1K</td>
<td align="right">19</td>
<td align="right">5</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$94.2</td>
<td>$89.75</td>
<td>$91.15</td>
<td>$435.00</td>
<td>$72.9K</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$35.4</td>
<td>$35.0</td>
<td>$35.4</td>
<td>$510.00</td>
<td>$56.6K</td>
<td align="right">630</td>
<td align="right">16</td>
</tr>
</tbody>
</table>

<h3>About Adobe</h3>
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
Having examined the options trading patterns of Adobe, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Adobe</h3>
<ul>
<li>Trading volume stands at 793,772, with ADBE's price up by 0.47%, positioned at $521.18.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 15 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Adobe, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

ADBE

Decoding Adobe's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bearish stance on Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMAT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Applied Mat.
This isn't normal.
The overall sentiment of these big-money traders is split between 20% bullish and 60%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $73,924, and 8 are calls, for a total amount of $632,367.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $135.0 and $250.0 for Applied Mat, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Applied Mat's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Applied Mat's significant trades, within a strike price range of $135.0 to $250.0, over the past month.
<h3>Applied Mat 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732641397_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$12.1</td>
<td>$11.9</td>
<td>$11.9</td>
<td>$210.00</td>
<td>$142.8K</td>
<td align="right">177</td>
<td align="right">131</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$20.25</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$200.00</td>
<td>$120.0K</td>
<td align="right">663</td>
<td align="right">61</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$21.6</td>
<td>$21.0</td>
<td>$21.6</td>
<td>$195.00</td>
<td>$114.4K</td>
<td align="right">143</td>
<td align="right">12</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$14.55</td>
<td>$14.3</td>
<td>$14.3</td>
<td>$220.00</td>
<td>$85.8K</td>
<td align="right">496</td>
<td align="right">0</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$20.25</td>
<td>$19.95</td>
<td>$20.0</td>
<td>$200.00</td>
<td>$50.0K</td>
<td align="right">663</td>
<td align="right">86</td>
</tr>
</tbody>
</table>

<h3>About Applied Mat</h3>
Applied Materials is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
In light of the recent options history for Applied Mat, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Applied Mat</h3>
<ul>
<li>With a volume of 1,763,966, the price of AMAT is down -1.72% at $171.54. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 79 days.</li>
</ul>
<h3>What The Experts Say On Applied Mat</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $227.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $250. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Applied Mat, targeting a price of $210. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Applied Mat with a target price of $225. 
&#x2A; An analyst from TD Cowen persists with their Buy rating on Applied Mat, maintaining a target price of $230. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Applied Mat, maintaining a target price of $220. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Applied Mat options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

AMAT

Check Out What Whales Are Doing With AMAT

Financial giants have made a conspicuous bearish move on IBM. Our analysis of options history for IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) revealed 18 unusual trades.
Delving into the details, we found 38% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $339,800, and 14 were calls, valued at $810,114.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $185.0 to $300.0 for IBM over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for IBM's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of IBM's whale activity within a strike price range from $185.0 to $300.0 in the last 30 days. 
<h3>IBM Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732641391_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$27.75</td>
<td>$27.7</td>
<td>$27.75</td>
<td>$240.00</td>
<td>$249.7K</td>
<td>119</td>
<td align="right">104</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$41.45</td>
<td>$40.95</td>
<td>$41.0</td>
<td>$200.00</td>
<td>$196.8K</td>
<td>2.5K</td>
<td align="right">1</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$23.7</td>
<td>$23.7</td>
<td>$23.7</td>
<td>$210.00</td>
<td>$85.3K</td>
<td>655</td>
<td align="right">48</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$6.65</td>
<td>$6.25</td>
<td>$6.25</td>
<td>$220.00</td>
<td>$62.5K</td>
<td>576</td>
<td align="right">144</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.05</td>
<td>$5.85</td>
<td>$5.9</td>
<td>$230.00</td>
<td>$59.0K</td>
<td>2.9K</td>
<td align="right">26</td>
</tr>
</tbody>
</table>

<h3>About IBM</h3>
IBM looks to be a part of every aspect of an enterprise's IT needs. The company primarily sells software, IT services, consulting, and hardware. IBM operates in 175 countries and employs approximately 350,000 people. The company has a robust roster of 80,000 business partners to service 5,200 clients, which includes 95% of all Fortune 500. While IBM is a B2B company, IBM's outward impact is substantial. For example, IBM manages 90% of all credit card transactions globally and is responsible for 50% of all wireless connections in the world.
<h3>Where Is IBM Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,344,450, the price of IBM is down by -0.06%, reaching $225.99.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 57 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for IBM with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

IBM Unusual Options Activity For November 26

Oppenheimer analyst Rick Schafer maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Outperform and raises the price target from $90 to $110.

MRVL

Oppenheimer Maintains Outperform on Marvell Tech, Raises Price Target to $110

Warning: ALLK is at high risk of performing badly

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

TD Cowen analyst Joseph Thome maintained a Hold rating on Allakos (ALLK – Research Report) today. The company's shares closed yesterday at $1.41. T...

Allakos (ALLK) Gets a Hold from TD Cowen

Allakos GAAP EPS of -$0.21 beats by $0.03

Barclays analyst Carter Gould maintained a Sell rating on Allakos (ALLK – Research Report) today and set a price target of $1.00. The company's sha...

Allakos (ALLK) Gets a Sell from Barclays

Allakos Runs Up Into A Near-Term Catalyst

Leerink Partners analyst Thomas Smith reiterated a Hold rating on Allakos (ALLK – Research Report) yesterday and set a price target of $2.00. Thoma...

Cautious Hold Rating for Allakos Amid Uncertain Clinical and Financial Outlook

Allakos ( ($ALLK) ) has provided an announcement. Allakos Inc. has entered into a Lease Termination Agreement with its landlord, significantly alte...

Allakos Inc. Alters Lease Agreement for Cost Savings

Allakos ( ($ALLK) ) has released its Q3 earnings. Here is a breakdown of the information Allakos presented to its investors. Allakos Inc. is a biot...

Allakos Reports Q3 2024 Results and Research Progress

AKBA

ALLK

APVO

CNSP

CRMD

CYCC

DBVT

GNPX

IMUX

MBIO

ONCT

SGMO

SYRS

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc.  - ALLK

Legal

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

Earnings

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

Comments

Allakos

Allakos (ALLK) Opzioni

Allakos (NASDAQ:ALLK) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO